Pharmavite   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Northridge CA United States (1971)
Status: No NME R&D (1971)

Organization Overview

First Clinical Trial
2008
NCT00722124
First Marketed Drug
1976
isoniazid (nydrazid)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Pharmavite | PHARMAVITE | Pharmavite LLC

Active Ingredients

Marketed Drugs (6)

dexchlorpheniramine maleate (polaramine) (1977)

isoniazid (nydrazid) (1976)

meprobamate (equanil)

prednisone (meticorten)

quinidine

reserpine (serpasil)

Drugs in Phase 4 Trials (3)

docosahexaenoic acid (1 trial)

eicosapentanoic acid (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

Drugs in Phase 3 Trials (1)

s-adenosyl methionine (1 trial)

Drugs in Phase 2 Trials (1)

vitamin d3 (2 trials)

Drugs in Phase 1 Trials (1)

melatonin (1 trial)

Drugs in Other Trials (1)

s-equol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Colonic Neoplasms (Phase 1)

Liver Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms, Second Primary (Phase 1)

Tobacco Use Disorder (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7